HBW
SRPT icon

Hazlett, Burt & Watson’s Sarepta Therapeutics SRPT Stock Holding History

Hazlett, Burt & Watson’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$1K – 859
2025
Q1 		$1K Sell
10
-20
-67% -$2.1K ﹤0.01% 773
2024
Q4 		$3K Buy
+30
New +$3.68K ﹤0.01% 678

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Hazlett, Burt & Watson's SRPT Position: Q2 2025 in Review

Hazlett, Burt & Watson sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 10 shares — an estimated $1K sold.

Hazlett, Burt & Watson first reported a position in SRPT in Q4 2024 and held it in 2 quarters. The position peaked at $3K in Q4 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Hazlett, Burt & Watson reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Hazlett, Burt & Watson sold 10 Sarepta Therapeutics shares in Q2 2025, an estimated $1K.
  • Hazlett, Burt & Watson first reported a position in Sarepta Therapeutics in Q4 2024 and held it in 2 quarters.
  • Hazlett, Burt & Watson's Sarepta Therapeutics position peaked at $3K in Q4 2024.
  • 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Hazlett, Burt & Watson's 13F filing for Q2 2025, filed 25 Jul 2025.